

CROATIAN JOURNAL OF ONCOLOGY

LIBRI ONCOLOGICI

50
1972.-2022.



LIBRI ONCOL. ISSN 0300-8142
UDK 616 – 006

2022 Vol. 50 Suppl. 1

VOLUMEN 50

NUMERUS suppl 1

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2022

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Petar Suton – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Željko Herceg, Ljiljana Mayer, Aleksandar Milenović, Marija Pastorčić-Grgić, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Sanda Šitić, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), G. Fisher (Stanford, USA), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), D. Marčinko (Zagreb, Croatia), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), R. Pirker (Wien, Austria), B.I. Šikić (Stanford, USA), I. Tomaš (Osijek, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA), M. Zovak (Zagreb, Croatia).

Indexed in SCOPUS and EMBASE/Excerpta Medica

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 60 HRK. Annual subscription rates in Croatia: 300 HRK + VAT for institutions, 150 HRK + VAT for individuals and 60 HRK + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb



15. HRVATSKI ONKOLOŠKI KONGRES 15th CROATIAN ONCOLOGY CONGRESS

31. 03. - 03. 04. 2022.
Opatija, Centar Gervais

Supplement editors:
Eduard Vrdoljak and Marijana Jazvić

Zagreb, Croatia
April, 2022

ORGANIZER

Hrvatsko onkološko društvo - Hrvatski liječnički zbor
Croatian society of Oncology

Organizing committee:

President: Eduard Vrdoljak

Vice President: Stjepko Pleština

Secretaries: Antonio Juretić, Damir Gugić, Ingrid Belac Lovasić

Lidija Beketić Orešković, KBC Sestre milosrdnice; Tanja Čufer, Medical Faculty Ljubljana; Višnja Matković, KBC Zagreb; Miroslav Samaržija, KBC Zagreb; Mladen Solarić, KBC Zagreb; Stipislav Jadrijević, KB Merkur; Nina Dabelić, KBC Sestre milosrdnice; Marijo Boban, KBC Split – Firule; Marko Zelić, KBC Rijeka; Snježana Tomić, KBC Split, Medicinski fakultet (UniZg); Ante Ćorušić, KBC Zagreb; Martina Bašić Koretić, KBC Zagreb – Rebro; Josipa Flam, KBC Osijek

Scientific committee:

Tanja Badovinac-Črnjević, Hrvatsko onkološko društvo; Goran Golčić, KBC Rijeka; Davor Štimac, KBC Rijeka; Marko Jakopović, KBC Zagreb – Jordanovac; Tomislav Omrčen, KBC Split – Firule; Boris Ružić, KBC Sestre milosrdnice; Sven Seiwerth, Medicinski fakultet, UniZg; Hrvoje Šobat, KBC Sestre milosrdnice; Dag Zahirović, KBC Rijeka; Ariana Znaor, Hrvatski registar za rak; Inga Marjanović, Sveučilišna klinička bolnica Mostar; Branka Petrić Miše, KBC Split; Marijana Jazvić, KBC – Sestre Milosrdnice; Jasna Radić, KBC – Sestre Milosrdnice

Sponsors and exhibitors:

ABBOTT

ALTAMEDICS

AMGEN

ASTELLAS

ASTRAZENECA

BAUSCHHEALTH

BAYER

Boehringer Ingelheim

Bristol-Myers Squibb

ELI LILLY

FARMEX

“JANSSEN: PHARMACEUTICAL COMPANIES OF JOHNSON&JOHNSON”

MERCK

MODRA JAGODA

MSD

MYLAN

NOVARTIS

OKTAL PHARMA

PFIZER

PHARMASWISS

PLIVA

ROCHE

SANDOZ

SANOFI GENZYME

SERVIER

ZENTIVA

Contents

ORAL PRESENTATIONS

Aleksandrova Stanojević Anastazija, Mlinarić Koprivanac Tena, Kuharić Josip S1 - A case report - uterine leiomyosarcoma	3
Perić Luka, Šambić Penc Mirela, Canjko Ivana, Flam Josipa, Kovač Barić Maja, Krivdić Dupan Zdravka, Pušeljić Nora S2 - Adjuvant treatment of testicular cancers	5
Jakšić Blanka, Prgomet Sečan Angela, Frobe Ana S3 - Brachytherapy in the treatment of gynaecological tumors	7
Bukovica Petrc Ana-Marija, Radojčić Milan, Belac-Lovasić Ingrid S4 - Case report of locally advanced non-small-cell lung cancer	8
Jajac Bručić Lana, Jović Zlatović Josipa S5 - Case report: the patient initially diagnosed with hormone receptor positive, HER 2 negative metastatic breast cancer (HR+/HER2- MBC) with aquired resistance to endocrine therapy	9
Brnić Senija S6 - Chronic complications of breast cancer treatment – physiatrist view	11
Murgić Jure, Fröbe Ana S7 - Do we treat prostate cancer according to guidelines?	14
Strikić Ante S8 - Have we made any progress in treating metastatic urothelial cancer?	16
Jakopović Marko, Bitar Lela, Seiwerth Fran, Samaržija Miroslav S9 - Immunotherapy of lung cancer, what does the future brings?	18
Omrčen Tomislav S10 - Individualization of treatment of oligometastatic colorectal cancer	20
Flam Josipa, Šambić Penc Mirela, Canjko Ivana, Perić Luka S11 - Can we get better at treating hepatocellular cancer?	22
Gnjidić Milena S12 - Metastatic renal cell carcinoma: an individualized approach to first-line treatment	24

Jazvić Marijana, Murgić Jure, Miletić Marija, Tomašković Igor, Bokarica Pero, Fröbe Ana	
S13 - Multidisciplinary approach to neoadjuvant treatment of urothelial cancer - oncologist's perspective	26
Tomašković Igor, Jazvić Marijana, Murgić Jure, Miletić Marija, Bokarica Pero, Nikles Sven, Pezelj Ivan, Tomić Miroslav	
S14 - Multidisciplinary approach to neoadjuvant treatment of urothelial cancer - urologist's perspective	28
Purgar Levarda Neva, Prpić Marin, Kust Davor, Fröbe Ana	
S15 - Nasopharyngeal cancer – case presentation	30
Radić Jasna, Marić Brozić Jasmina, Fröbe Ana	
S16 - New developments in neoadjuvant and adjuvant treatment of non-small cell lung cancer	32
Petrić Miše Branka	
S17 - News in luminal breast cancer treatment	34
Rakusic Zoran	
S18 - News in the treatment of head and neck cancers	37
Boban Marijo	
S19 - Novelties in targeted therapy of the non-small cell lung cancer	39
Bašić Koretić Martina, Podolski Paula, Šarić Nera, Soče Majana, Baučić Maja, Vušković Sanja	
S20 - Novelties in treatment of HER2-positive breast cancer	41
Bitar Lela, Srdić Dražena, Seiwerth Fran, Jakopović Marko	
S21 - NSCLC with KRAS G12C mutation treatment – a case report	43
Tomić Snježana	
S22 - PAN-tumor biomarkers in era of agnostic oncology	44
Ban Marija	
S23 - Pancreatic cancer: current standards and future perspectives	46
Šunjić Marin, Soldić Željko, Fröbe Ana	
S24 - Perioperative chemotherapy in locally advanced gastric cancer-case report	48
Čerina Dora, Tica Sedlar Ivana	
S25 - Personalization of the approach to the metastatic uterine cancer: a case report	49
Antunac Katarina	
S26 - Positioning of intraoperative radiotherapy in breast cancer treatment	50
Solaric Mladen	
S27 - Prostate cancer - surgery or radiotherapy?	52
Belac Lovasić Ingrid, Pavlović-Ružić Ira, Zahirović Dag	
S28 - Radiotherapy network in Croatia	53

Rendić-Miočević Zrinka, Beketić-Orešković Lidija	
S29 - Metastatic spinal cord compression – radiotherapy	55
Zahirović Dag	
S30 - Oncological treatment of sarcomas	57
Dabelić Nina, Jukić Tomislav, Fröbe Ana	
S31 - Systemic oncologic treatment of thyroid cancer	59
Marušić Jasna	
S32 - Systemic treatment of cervical cancer	61
Nalbani Mario, Curic Zvonimir	
S33 - The importance of multigene testing in the selection of adjuvant breast cancer treatment	63
Jerković Ivona, Golčić Marin, Redžović Arnela, Belac-Lovasić Ingrid	
S34 - The importance of multimodality treatment for metastatic colorectal cancer: a case report	66
Vrljičak Antonela, Urch Kristina, Dabelić Nina, Marić Brozić Jasmina, Fröbe Ana	
S35 - Toxicities associated with melanoma treatment - a case report	67
Canjko Ivana, Perić Luka, Šambić-Penc Mirela, Flam Josipa, Kovač Barić Maja, Krivdić Dupan Zdravka, Kotromanović Darko	
S36 - Treatment of oligometastatic non-small cell lung cancer	68
Redžović Arnela, Miletić Marija, Belac-Lovasić Ingrid	
S37 - Treatment of penile cancer	70
Simetić Luka, Blažičević Krešimir, Herceg Davorin	
S38 - Treatment of rare primary melanomas	72
Boraska Jelavić Tihana	
S39 - What is new in first-line ovarian cancer treatment?	74
Bišof Vesna	
S40 - What is new in the treatment of oesophageal and gastroesophageal junction cancers?	76
Tečić Vuger Ana, Šeparović Robert	
S41 - What is new in the treatment of triple negative breast cancer	78
Buhovac Teo, Marijanović Inga	
S42 - Young woman with metastatic breast cancer – problems and needs: a case report	80
Belev Borislav	
S43 - Immunotherapy in gastrointestinal cancer – unfulfilled aim in Croatia	82

POSTER PRESENTATIONS

Kotromanović Darko, Šimić Ivana, Prpić Tin, Kotromanović Željko, Kotromanović Zdenka, Canjko Ivana, Kotromanović Sonja, Perić Luka, Tomaš Ilijan P1 - Review of second primary tumors in patients with head and neck cancer in University Hospital Center Osijek from 2017 to 2021	87
Jakšić Petra, Linarić Petra, Jezernik Dejana, Kanceljak Kristina, Tečić Vuger Ana, Pavlović Mavić Mirjana, Vazdar Ljubica, Šeparović Robert P2 - Assessment of cutaneous toxicity in cancer patients treated with CDK 4/6 inhibitors and endocrine therapy according to patient-related outcomes at the University Hospital for tumors	88
Franceschi Dora, Murgić Jure, Miletić Marija, Jazvić Marijana, Tomić Miroslav, Nikles Sven, Fröbe Ana P3 - Association between pretreatment neutrophil-to-lymphocyte ratio and outcome of patients with metastatic renal cell carcinoma treated with nivolumab – a single institution analysis	89
Novak Kosjenka, Car Peterko Ana, Rajković Molek Koraljka, Gulić Tamara, Veljković Vujaklija Danijela, Belac Lovasić Ingrid, Lovasić Franjo, Mustać Elvira, Avirović Manuela P4 - Associations of tils components CD8, CD4, PD-L1, CTLA4 and FOXP3 in triple negative breast carcinoma with the clinicopathological prognostic factors . . .	91
Ežbegović Bruno, Canjko Ivana, Rimac Nada P5 - Breathing exercise impact on quality of life with lung cancer patients	92
Paradžik Pašalić Vanda, Matković Višnja, Vujić Goran, Planinić Pavao, Škvorc Marko, Lovrić Gršić Helena P6 - Cervical cancer in pregnancy - a case report	93
Petrić Miše Branka, Odak Maja, Vrdoljak Eduard P7 - Clinical characteristics of BRCA mutated patients with high grade serous ovarian cancer – single center experiences from University Hospital of Split . . .	95
Petrić Miše Branka, Katalenić Monika, Vrdoljak Eduard P8 - Clinical characteristics of patients with hereditary breast and ovarian cancer – single center experiences from University Hospital of Split . . .	96
Brčić Hrvoje, Radić Jasna, Marić Brozić Jasmina, Murgić Jure, Urch Kristina, Purgar Levarda Neva, Fröbe Ana P9 - Clinical outcomes of patients with metastatic non-small cell lung cancer treated with pembrolizumab monotherapy or in combination with chemotherapy – updated analysis of a single center experience	97
Nalbani Mario, Jajac Bručić Lana, Telesmanić Dobrić Vesna, Strikić Ante P10 - Collaboration of Dalmatian Hospitals: impact of COVID-19 on the reported incidence of breast cancer in the first wave of the pandemic in Dalmatia	98

<p>Čerina Dora, Buljubašić Franić Matea, Šuto Jelena, Urlić Ivanka, Pancirov Marija, Vrdoljak Eduard</p> <p>P11 - Combination of the gemcitabine and paclitaxel in the second line treatment setting after progression to folfirinox - a single institution analysis at the Department of oncology and radiotherapy, University Hospital of Split</p>	100
<p>Ramljak Vesna, Nikic Vivian, Skerlj Marija, Agai Muhaxhiri Merdita, Bobus Kelcec Iva, Kirac Iva</p> <p>P12 - Comparison of er and pr receptor and HER2 analysis between cell blocks and pathology samples</p>	101
<p>Radić Petra, Fekete Petar, Novosel Luka, Sjekavica Ivica</p> <p>P13 - Comparison of percutaneous CT-guided microwave ablation and partial nephrectomy in the treatment of T1A renal carcinoma</p>	102
<p>Belić Dino, Flam Josipa, Šambić Penc Mirela, Canjko Ivana, Kasabašić Mladen</p> <p>P14 - Comparison of radiotherapy techniques – experiences of a Clinical Hospital Center</p>	103
<p>Obajdin Nevena, Smilović Radojčić Đeni, Rajlić David, Švabić Kolacio Manda, Jurković Slaven</p> <p>P15 - Comparison of three calculation algorithms for post-operative radiotherapy of breast cancer</p>	104
<p>Čerina Dora, Buljubašić Matea, Majić Ana, Pancirov Marija, Šuto Jelena, Vrdoljak Eduard</p> <p>P16 - Comprehensive genomic profiling (CGP) in the upfront diagnostic workup of locally advanced or metastatic ovarian cancer- a single institution analysis</p>	105
<p>Telesmanić Dobrić Vesna, Jajac Bručić Lana, Nalbani Marijo, Strikić Ante</p> <p>P17 - COVID9 impact on reported incidence of colorectal cancer during the first wave of pandemic in Dalmatia</p>	107
<p>Tomić Krešimir, Berić Jozić Gordana, Miletić Dragana, Parić Ana, Marijanović Inga</p> <p>P18 - COVID-19 pandemic impact on radiotherapy in patients with head and neck cancer</p>	108
<p>Rajlić David, Smilović Radojčić Đeni, Švabić Kolacio Manda, Obajdin Nevena, Jurković Slaven</p> <p>P19 - Development and implementation of 2d radiochromic film dosimetry methodology for verification of advanced radiation therapy technique delivery as a part of IAEA CRO 6019 project</p>	109
<p>Bošković Lidija, Hrepić Dario, Boban Marijo, Boraska-Jelavić Tihana, Viculin Jelena, Vrdoljak Eduard</p> <p>P20 - Durvalumab in the treatment of stage III NSCLC – single center experience</p>	110
<p>Petrić Miše Branka, Pešo Mirko, Hrepić Darijo, Vrdoljak Eduard</p> <p>P21 - Efficacy and safety of olaparib in the treatment of BRCA mutated ovarian cancer – single center experience from University Hospital of Split</p>	111

Omrčen Tomislav, Hrepić Dario, Katić Andrija, Radić Jasna, Prejac Juraj, Belev Borislav P22 - Efficacy of ramucirumab in combination with paclitaxel in the second line treatment of metastatic gastric cancer – retrospective analysis from three Croatian Oncology Centers	113
Buljubašić Franić Matea, Čerina Dora, Šuto Jelena, Urlič Ivanka, Pancirov Marija, Vrdoljak Eduard P23 - Folfirinox vs. gemcitabine + NAB-paclitaxel in the first line treatment setting of metastatic pancreatic cancer – a single institution analysis of the outcomes	114
Berić Jozić Gordana, Tomić Krešimir, Čale Sanda, Marijanović Inga P24 - How often oncologists record the patients' COVID-19 infection in their findings	116
Petrić Miše Branka, Pešo Mirko, Hrepić Darijo, Vrdoljak Eduard P25 - How to sequence chemotherapy after progression to olaparib maintenance therapy in patients with BRCA mutated ovarian recurrence? – single center experience from University Hospital of Split	117
Murgić Jure, Jazvić Marijana, Miletić Marija, Franceschi Dora, Prgomet Sečan Angela, Ulamec Monika, Šoipi Šoip, Fröbe Ana P26 - Immune checkpoint inhibitors in the treatment of metastatic urothelial cancer: a single-center retrospective study	118
Urch Kristina, Franceschi Dora, Jazvić Marijana, Soldić Željko, Fröbe Ana P27 - Impact of the COVID-19 pandemic on breast cancer presentation at UHC Sestre milosrdnice	120
Berić Jozić Gordana, Tomić Krešimir, Marijanović Inga P28 - Inpatient oncology care – impact of COVID-19 pandemic, single-center experience	121
Tudor Filip, Maršić Matej, Malvić Goran, Hadžisejdić Ita, Maržić Diana, Braut Tamara, Velepich Marko, Marijić Blažen P29 - Is frontolateral laryngectomy still useful procedure in the treatment of laryngeal malignancy in the modern era?	122
Čuljak Željka, Vrdoljak Eduard, Boraska Jelavić Tihana P30 - Long-lasting complete response on third-line immunotherapy in patient with malignant pleural mesothelioma – case report	123
Car Peterko Ana, Avirović Manuela, Grebić Damir, Juranić Damir, Mustać Elvira, Trčak Danijel, Bila Aleksandra, Brajan Dolores, Žepina Nevija, Golubovac Iskra Mladenka, Tomić Snježana, Perić Balja Melita, Milković Periša Marija, Tomasović Čedna, Lovasić Franjo P31 - Mastectomy should not be offered to the early-stage breast cancer patients	125
Urch Kristina, Šunjić Marin, Marić Brozić Jasmina, Dabelić Nina, Murgić Jure, Fröbe Ana P32 - Melanoma patients with brain metastasis – a single-center experience	126

Guljaš Silva, Perković Josip, Pavlović Oliver, Krajina Vinko, Pavoković Deni P33 - Multiparametric magnetic resonance imaging for bladder carcinoma	127
Pleško Eva, Dedić Plavetić Natalija P34 - Neoadjuvant chemotherapy in patients with breast cancer, ATM mutation carriers	128
Marijić Blažen, Janik Stefan, Grasl Stefan, Grasl Matthäus Christoph, Tudor Filip, Erovic Boban M. P35 - Outcome of patients with advanced laryngeal carcinoma - a multicentric retrospective study	129
Vrljičak Antonela, Murgić Jure, Jazvić Marijana, Soldić Željko, Fröbe Ana P36 - Palliative radiotherapy (PR) for bone metastases – patterns of care and outcomes analysis from a large tertiary center	131
Perić Luka, Flam Josipa, Canjko Ivana, Šambić Penc Mirela, Kotromanović Darko, Pušeljić Nora, Tomaš Ilijan P37 - Patients with leptomeningeal metastases, their treatment and outcome	132
Petrić Miše Branka, Katalenić Monika, Tomić Snježana, Kuret Sendi, Drmić Hofman Irena, Vrdoljak Eduard P38 - Pathological characteristics and spectrum of BRCA mutations in patients with hereditary breast and ovarian cancer – single center experiences from University Hospital of Split	133
Jajac Bručić Lana, Nalbani Mario, Telesmanić Dobrić Vesna, Strikić Ante P39 - Prostate cancer in the first wave of pandemic: has COVID-19 changed the perspective of prostate cancer	135
Baturina Blanka, Heinrich Zdravko, Hršak Hrvoje, Hrepić Darijo, Boraska Jelavić Tihana P40 - Re-planning in gamma knife radiosurgical centre	136
Car Peterko Ana, Avirović Manuela, Valković Zujic Petra, Brajan Dolores, Mustać Elvira, Rajković Molek Koraljka, Seili Bekafigo Irena, Belac Lovasić Ingrid, Cini Tešar Eleonora, Giroto Neva, Grebić Damir, Juranić Damir, Žepina Nevija, Golubovac Iskra Mladenka, Lončarek Karmen, Jakšić Nataša, Dekanić Arbanas Gracia, Lovasić Franjo P41 - Setting up the first quality-assured specialized breast centre in Croatia	138
Murgić Jure, Jazvić Marijana, Miletić Marija, Franceschi Dora, Prgomet Sečan Angela, Kuharić Ivan, Tomašković Igor, Fröbe Ana P42 - Single institution experience with nivolumab as second line therapy in advanced renal cell carcinoma: exploratory analysis of prognostic factors	139
Petrić Miše Branka, Odak Maja, Tomić Snježana, Kuret Sendi, Drmić Hofman Irena, Vrdoljak Eduard P43 - Spectrum of BRCA1 and BRCA2 mutations in patients with high grade serous ovarian cancer in Dalmatia – single center experience from University Hospital of Split	141

Krivdić Dupan Zdravka, Canjko Ivana, Guljaš Silva, Šarić Gordan, Šambić Penc Mirela, Prlić-Seršić Ingrid, Dumačić Dijana P44 - Spectrum of radiological imaging findings of immune-checkpoint blockade for lung cancer at University Hospital Centre Osijek	142
Krivdić Dupan Zdravka, Canjko Ivana, Guljaš Silva, Šarić Gordan, Šambić Penc Mirela, Rončević Robert, Perić Luka P45 - Spectrum of radiological imaging findings of specific target therapy for lung cancer at University Hospital Centre Osijek	144
Ramić Snježana, Cesarec Augustinović Sanja, Puhalo Ana, Karačić Ena, Perić Balja Melita P46 - Subtyping of triple-negative breast cancer	145
Majić Ana, Tica Seldar Ivana, Vrdoljak Eduard P47 - The potential of combination therapy with fulvestrant and letrozole in neoadjuvant hormonal therapy of breast cancer	146
Gamulin Marija, Baučić Maja, Magličić Ana, Bajan Manuela, Koši Kunac Ana P48 - The treatment results of mrcr patients 6 years after first application of nivolumab as second line therapy	148
Erceg Tušek Maja, Vukota Ljiljana P49 - The unmet needs of cancer patients - a step forward	149
Viculin Jelena, Ban Marija, Bošković Lidija, Katić Andrija, Buljubašić Matea, Vrdoljak Eduard P50 - The up-dated insight into immunotherapy with checkpoint inhibitors in patients with metastatic colorectal cancer - our daily practice	150
Šuto Jelena, Čerina Dora, Buljubašić Franić Matea, Urlić Ivanka, Pancirov Marija, Vrdoljak Eduard P51 - Transition throughout the treatment lines and the outcomes of metastatic pancreatic cancer at the Department of oncology and radiotherapy, University Hospital of Split during 2018-2021 - a retrospective analysis.	152
Boban Marijo, Buljubašića Matea, Hrepić Darijo, Katića Andrija, Vrdoljaka Eduard P52 - Treatment of patients with esophageal carcinoma - experience of the Department of oncology, University Hospital of Split	153
Katić Andrija, Omrčen Tomislav, Viculin Jelena, Boban Marijo, Hrepić Darijo, Vrdoljak Eduard P53 - Treatment patterns and survival outcomes of patients with metastatic gastric cancer at the Department of oncology and radiotherapy, University Hospital of Split from 2018 to 2020 - a retrospective analysis.	154
AUTHOR INDEX	157